If you’ve started a GLP-1 medication and noticed your heart beating faster or harder than usual, you’re not alone. Heart palpitations are reported across the entire class of GLP-1 receptor agonists, including semaglutide and tirzepatide. They’re usually benign, tied to predictable biological mechanisms, and tend to resolve as your body adjusts. But knowing what’s driving them and when to take them seriously makes a real difference in how you manage treatment.<\/p>\n
GLP-1 receptors aren’t found only in the gut and pancreas. They’re distributed throughout the body, including in cardiac tissue. When a GLP-1 receptor agonist activates those receptors, it produces a modest but measurable increase in resting heart rate. Across clinical trials for both semaglutide and tirzepatide, this increase averages around two to four beats per minute. For most people that’s imperceptible. For others, particularly those who are sensitive to cardiovascular changes or who are in the early weeks of treatment, it can register as a noticeable flutter or pounding sensation.<\/p>\n
This is a class effect, meaning it applies to all GLP-1 medications to varying degrees, not just one specific drug.<\/p>\n
Both semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) can cause mild heart rate elevation. Tirzepatide works through both GLP-1 and GIP receptors, which gives it a slightly different cardiovascular profile than pure GLP-1 agonists. Clinical data suggests the heart rate increase with tirzepatide is comparable to semaglutide, though individual responses vary.<\/p>\n
The practical takeaway is that if you experience palpitations on one GLP-1 medication, switching to another in the same class isn’t guaranteed to eliminate the symptom. That said, some patients do report differences in how their body responds to each medication, and your provider can help weigh whether a switch makes sense in your specific situation.<\/p>\n
The direct cardiac effect of GLP-1 receptor activation is only part of the story. Several indirect factors contribute significantly.<\/p>\n
Reduced appetite and nausea in the early weeks of treatment often lead to inadequate fluid and food intake. When electrolytes like potassium and magnesium drop, the electrical conduction system of the heart is directly affected. Low magnesium in particular is a well-established trigger for palpitations and is surprisingly common in patients who have significantly reduced their food intake.<\/p>\n
Blood glucose shifts, whether dropping too low or stabilizing from previously elevated levels, can trigger a brief increase in heart rate. Patients taking other diabetes medications alongside a GLP-1 agonist are at higher risk for hypoglycemia, which produces adrenaline release and a characteristic racing heartbeat.<\/p>\n
A significant caloric deficit activates the sympathetic nervous system as part of the body’s adaptation response. That sympathetic activation can increase heart rate and produce the sensation of palpitations even in the absence of direct cardiac pathology.<\/p>\n
Consider this scenario: a patient starts tirzepatide and within three weeks is eating around 1,000 fewer calories per day than before. They’re also drinking less because their appetite and thirst are both blunted. By week four they’re waking at night with a pounding heart. Once they prioritize consistent hydration, add an electrolyte supplement, and eat more regularly throughout the day, the nighttime palpitations resolve within two weeks.<\/p>\n
It’s worth stepping back to look at the broader cardiovascular evidence for GLP-1 medications, because the mild heart rate increase exists within a much more positive overall cardiac profile.<\/p>\n
Large cardiovascular outcomes trials have shown meaningful benefits for high-risk patients. Research published in the New England Journal of Medicine demonstrated that semaglutide significantly reduced the risk of major adverse cardiovascular events, including heart attack and stroke, in patients with established cardiovascular disease. Tirzepatide’s cardiovascular outcomes data from the SURPASS-CVOT trial has similarly shown a favorable profile.<\/p>\n
The modest heart rate increase, in other words, doesn’t appear to translate into worse cardiac outcomes. For most patients the net cardiovascular effect of GLP-1 treatment is positive, particularly as weight loss progresses and blood pressure improves.<\/p>\n
Mild, brief, infrequent palpitations in the early weeks of treatment are generally not a cause for alarm. The following patterns are different and warrant prompt medical evaluation.<\/p>\n
Palpitations that last more than a few minutes without resolving deserve attention. So do palpitations accompanied by chest tightness, shortness of breath, or lightheadedness. Fainting or near-fainting alongside a racing heart is always an urgent concern. And palpitations that are getting progressively worse with each passing week rather than improving are a signal to check in with your provider sooner rather than later.<\/p>\n
Patients with pre-existing arrhythmias, structural heart disease, or a history of significant cardiac events should discuss GLP-1 treatment with their cardiologist before starting, not just their primary care provider.<\/p>\n
Most patients can reduce palpitation frequency and intensity with a few consistent habits.<\/p>\n
Hydrate consistently.<\/strong> Aim for at least 64 ounces of water daily. On GLP-1 medications, thirst signals are often blunted, so drinking on a schedule matters more than drinking when you feel thirsty.<\/p>\n Support electrolyte intake.<\/strong> Magnesium glycinate is widely used by patients on GLP-1 medications for both palpitations and muscle cramps. Potassium-rich foods like avocados, bananas, and sweet potatoes help maintain the electrolyte balance that supports normal heart rhythm.<\/p>\n Limit caffeine, especially early in treatment.<\/strong> Caffeine raises heart rate independently and can amplify the mild cardiac effects of GLP-1 receptor activation.<\/p>\n Eat regularly.<\/strong> Skipping meals entirely on a slowed gut can produce blood sugar swings that trigger the adrenaline response behind some palpitation episodes. Small, consistent meals help keep glucose stable.<\/p>\n Slow the dose escalation if needed.<\/strong> If palpitations are significant, your provider may recommend staying at a lower dose for longer before titrating up. There’s no clinical requirement to escalate on the fastest possible schedule.<\/p>\n For patients managing broader cardiovascular considerations alongside GLP-1 treatment, Ozempic and heart disease<\/a> covers eligibility and risk factors in more detail.<\/p>\n Palpitations are a real and common experience on GLP-1 medications. They’re also, in the vast majority of cases, manageable and temporary. Understanding the mechanisms behind them removes a lot of the anxiety that can make the early weeks of treatment harder than they need to be.<\/p>\nStarting Treatment With Confidence<\/h2>\n